• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Agilent Technologies Inc.

    5/27/25 4:05:09 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email
    SD 1 a-form_sd_re_cmr_1231202.htm SD SD

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM SD

    SPECIALIZED DISCLOSURE REPORT

    AGILENT TECHNOLOGIES, INC.

    (Exact name of the registrant as specified in its charter)

     

     

    DELAWARE

    001-15405

    77-0518772

    (State of incorporation)

    (Commission File Number)

    (IRS Employer Identification No.)

     

    5301 Stevens Creek Blvd., Santa Clara, California

    95051

    (Address of principal executive offices)

    (Zip code)

     

     

    P. Diana Chiu

    (800) 227-9770

    (Name and telephone number, including area code, of the person to contact
     in connection with this report.)

     

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

     Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

     

     

     

     

     

     


     

    Section 1 – Conflict Minerals Disclosure

    Item 1.01 – Conflict Minerals Disclosure

    Agilent Technologies, Inc. (“Agilent,” the “Company,” “we,” “us,” or “our”) is filing this Form SD pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended, for the reporting period January 1 to December 31, 2024.

    Agilent is a leader in life sciences, diagnostics, and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent's expertise and trusted collaboration give them the highest confidence in our solutions.

    This Form SD should be read in conjunction with the definitions contained in the Securities and Exchange Commission instructions to Form SD and related rules. “Conflict minerals” refers to four specific metals regardless of their country of origin or whether they are used to finance or benefit armed conflict: tantalum, tin, tungsten, and gold.

    With respect to conflict minerals necessary to the functionality of products manufactured by Agilent, or contracted by Agilent to be manufactured, and required to be reported on Form SD for 2024, we conducted a reasonable country of origin inquiry concerning the source and chain of custody of the conflict minerals and performed supply chain due diligence.

    A copy of Agilent’s Conflict Minerals Report for the reporting period of January 1 to December 31, 2024, is provided as Exhibit 1.01 hereto and is publicly available at investor.agilent.com/financials/sec-filings.

    Description of Reasonable Country of Origin Inquiry (“RCOI”)

    Because of our size, the complexity of our products, and the depth, breadth, and constant evolution of our supply chain, it is difficult to identify material sources upstream from our direct suppliers. We rely on our direct material suppliers to provide information on the origin of the conflict minerals contained in components, materials, and assemblies supplied to us - including sources of conflict minerals that are supplied to them from lower-tier suppliers.

    In undertaking our RCOI, we conducted a targeted survey of our direct material suppliers that represent 85 percent of spend, utilizing the Responsible Minerals Initiative (“RMI”) Conflict Minerals Reporting Template (“CMRT”) version 6.4. Our direct material supply chain personnel worked directly with our suppliers, requesting their responses to the questions in the RMI CMRT with respect to their 2024 sales to Agilent. Suppliers’ CMRTs were evaluated for completeness, accuracy of the information, and consistency in the responses to questions and smelter lists. The RMI databases were utilized as part of the assurance process. Suppliers were contacted regarding their CMRTs which contained errors and/or omissions and were requested to resubmit a corrected CMRT. This process occurred during the third calendar quarter of 2024 and the first calendar quarter of 2025.

    We believe this is a reasonable approach as it allowed us to canvas suppliers who represented more than 85 percent of our direct material expenditures in 2024.

    Item 1.01 Exhibit

    Agilent has included its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

     

    2


     

     

    SECTION 2 – EXHIBITS

     

    Item 2.01 Exhibits

     

    Exhibit No.

    Description

    1.01

    Conflict Minerals Report as required by Items 1.01 and 1.02 of Form SD

     

     

    3


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    AGILENT TECHNOLOGIES, INC.

    (Registrant)

     

     

     

    /s/P. Diana Chiu

     

     

     

    May 27, 2025

    By: P. Diana Chiu
    Vice President, Assistant General Counsel & Assistant Secretary

    Date

     

    4


    Get the next $A alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Gonsalves Rodney (Amendment)

      4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      10/20/23 1:07:25 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      9/29/23 4:03:46 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    See more
    • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

      Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

      4/24/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Acquire North American CDMO BIOVECTRA

      Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

      7/22/24 9:01:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care